Search for: "MYLAN, N.V." Results 21 - 34 of 34
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
1 Dec 2017, 6:26 am by Cameron Kennedy
The recall was from Meridian Medical Technologies / Mylan N.V., affecting 13 lots of products thought to have deployment defects. [read post]
1 Dec 2017, 6:26 am by Cameron Kennedy
The recall was from Meridian Medical Technologies / Mylan N.V., affecting 13 lots of products thought to have deployment defects. [read post]
5 Sep 2017, 7:45 am by Ben Vernia
Mylan Inc. and Mylan Specialty L.P. are both wholly owned subsidiaries of Mylan N.V., which is headquartered in Canonsburg, Pennsylvania. [read post]
20 Nov 2016, 5:17 pm by Kevin LaCroix
For example, according to Coffee, the drug pricing scandals that have hit Valeant  Pharmaceuticals and Mylan N.V. were the result of compensation schemes that as structured “incentivized” the executives at those companies to take risk. [read post]
28 Oct 2016, 2:35 pm by Laura Ray
Mylan N.V. recently “announced that its subsidiary, Mylan Inc., has agreed to the terms of a $465 million settlement with the U.S. [read post]
1 Dec 2015, 6:20 am
(“Mylan”), a NASDAQ-quoted Dutch public limited liability company (or, “Dutch N.V. [read post]
17 Nov 2015, 6:18 am
On Friday November 13, 2015, shareholders of Perrigo Company plc convincingly rejected Mylan N.V. [read post]
17 Nov 2015, 5:30 am by Broc Romanek
Here’s news from this Wachtell Lipton memo: On Friday, shareholders of Perrigo Company plc convincingly rejected Mylan N.V. [read post]
26 Aug 2015, 11:02 am by Lawrence B. Ebert
Mylan also has filed another petition for inter partes review of a related patent (U.S. [read post]
11 Jul 2015, 1:41 pm by joanheminway
I noted with favor the other day (to myself, privately) the helpful and interesting commentary on The Glom of our trusted colleague and co-blogger, Usha Rodrigues, regarding the recent press reports on Mylan N.V.'s related-party disclosures. [read post]
17 Feb 2010, 5:10 am
(Patent Docs) Razadyne (Galantamine) / Strattera (Atomoxetine) – US: Walking the enablement/non-obviousness tightrope: Janssen Pharmaceutica N.V. v. [read post]